Tempest Therapeutics grants director 25,000 stock options

Tempest Therapeutics director John D. Yee received a grant of stock options covering 25,000 shares of common stock.

Rhea-AI Filing Summary

Tempest Therapeutics director John D. Yee received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $1.27 per share and expire on June 4, 2036. This is a compensation-related award, not an open-market purchase.

According to the terms, one-third of the options vest on the first anniversary of the June 4, 2026 grant date, with the remaining two-thirds vesting in equal monthly installments over the following two years, conditioned on his continued service. After this grant, Yee holds stock options for 25,000 shares directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Yee John D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Key Figures

Option grant size: 25,000 options Exercise price: $1.27 per share Expiration date: June 4, 2036 +2 more

5 metrics

Option grant size 25,000 options Stock Option (right to buy) covering 25,000 underlying common shares

Exercise price $1.27 per share Conversion or exercise price of the stock options

Expiration date June 4, 2036 Option expiration date for the stock option grant

Post-transaction options held 25,000 options Total stock options held directly after this grant

Vesting period 3 years One-third after one year, remainder in equal monthly installments

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price": "1.2700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest over a three-year period, with one-third of the award vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tempest Therapeutics (TPST) disclose about John D. Yee in this Form 4?

Tempest Therapeutics reported that director John D. Yee received a grant of stock options for 25,000 shares of common stock at an exercise price of $1.27 per share, expiring on June 4, 2036, as part of his compensation.

Is the John D. Yee Form 4 for TPST a stock purchase or a grant?

The Form 4 for Tempest Therapeutics (TPST) shows a grant of stock options, not an open-market stock purchase. The transaction is coded “A” and described as a grant, award, or other acquisition of derivative securities as director compensation.

How many TPST shares are covered by John D. Yee’s new stock options?

The new stock option award to John D. Yee covers 25,000 underlying shares of Tempest Therapeutics common stock. These options give him the right to buy those shares at a fixed $1.27 per share exercise price before the stated expiration date.

What is the vesting schedule of John D. Yee’s TPST stock options?

The options vest over three years: one-third of the award vests on the first anniversary of the grant date, and the remaining two-thirds vest in equal monthly installments thereafter, subject to John D. Yee’s continued service with Tempest Therapeutics.

When do John D. Yee’s Tempest Therapeutics stock options expire?

John D. Yee’s Tempest Therapeutics stock options expire on June 4, 2036. He may exercise the vested portion at the $1.27 per share exercise price any time before that expiration date, subject to the company’s equity plan and applicable terms.

How many TPST stock options does John D. Yee hold after this transaction?

Following this transaction, John D. Yee holds 25,000 stock options directly, according to the Form 4. These options relate to Tempest Therapeutics common stock and reflect his position after the recorded grant in this specific filing snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 07:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yee John D.

(Last) (First) (Middle)

118 LEXINGTON ROAD

(Street)

LINCOLN MASSACHUSETTS 01773

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.27	06/04/2026		A		25,000		(1)	06/04/2036	Common Stock	25,000	$0.00	25,000	D

Explanation of Responses:

1. The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Remarks:

This transaction is being reported late due to an inadvertent administrative oversight.

	/s/ John David Yee	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)